Large gatherings have the potential to become “superspreader” events of
Read moreHome »
FDA Approves New Indication & New Product Formulation for Myrbetriq for Use in Children with Neurogenic Detrusor Overactivity (NDO)
TOKYO, March 26, 2021 /PRNewswire/ — Astellas Pharma Inc. (TSE:
Read moreFDA Expands Indication for Soliqua 100/33 (insulin glargine and lixisenatide injection) to Include Type 2 Diabetes Patients Uncontrolled on Oral Antidiabetic Medicines
BRIDGEWATER, N.J., Feb. 27, 2019 /PRNewswire/ — The U.S. Food
Read more